Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822573 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
A Phase 3 study of Cognitive Dysfunction and Memory Impairment, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT02822573: Completed Phase 3 study of Cognitive Dysfunction and Memory Impairment, sponsored by Wake Forest University Health Sciences.
NCT02822573 is a Phase 3 study of Cognitive Dysfunction and Memory Impairment that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 276 participants, below the 1,987-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02822573, a Phase 3 study of Cognitive Dysfunction and Memory Impairment, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to compare the safety and effects of donepezil (Aricept) for patients reporting cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory improves with the use of donepezil during the study.
Primary Outcome
Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R measures verbal learning and memory. It consists of a 12-item word list which is read to patients on three successive learning trials. Free recall scores are recorded for each learning trial. After a 20-minute interval during which patients complete other non-interfering tasks and questionnaires they are asked to recall the target words. Range is 0-36 with higher values representing better verbal learning and memory.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donepezil 5 mg
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente West Los Angeles - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Riverside - Riverside
- Kaiser Permanente-Roseville - Roseville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 3 |
What the finished NCT02822573 record still lists
NCT02822573 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 1,987-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02822573 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT02822573 about?
NCT02822573 is a clinical study titled "Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil". This study is to compare the safety and effects of donepezil (Aricept) for patients reporting cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory improves with the use of ...
What is the current status of trial NCT02822573?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2017-05-30. Estimated completion is 2022-07-29.
What conditions does trial NCT02822573 study?
This clinical trial studies the following conditions: Cognitive Dysfunction, Memory Impairment.
What interventions are being tested in trial NCT02822573?
The interventions under investigation include: Placebo (DRUG), Donepezil 5 mg (DRUG).
Who is sponsoring clinical trial NCT02822573?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02822573 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02822573's enrollment target sits among peer trials
276 12th of 45 higher than 34 of 45 other Cognitive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI